T 0054/82 (Disclosure) 16-05-1983

1. The appeal complies with Articles 106 to 108 and Rule 64 EPC and is therefore admissible.

2. The decision of the Examining Division is based upon the consideration that it is not permissible to combine the disclosure at page 1 of the specification as initially filed, that the oxazolines were made by reacting one mole of the acid with one or two moles of the aminomethane, and the disclosure in original example 3 of the use of a C18-24 acid. This consideration is based on the assumption that the test for additional subject-matter corresponds to the test for novelty and that in considering novelty, it is not permissible to combine separate items of information, including separate parts of the same document. The appellant contests both assumptions. In certain circumstances, he argues, it should be permissible to combine separate items of information, even if originating from different documents. The interpretation that it would not be permissible to combine separate parts of the same document is not countenanced by the Convention and is contrary to the basic rules for the interpretation of documents which rules include that documents must be read fairly and as a whole.

3. The Board of Appeal agrees with the appellant that there is nothing in the Convention which prohibits in all circumstances the reading together of different parts of a single document. Indeed the Examining Division itself stated in its decision (page 2, lines 22-27): "An amendment is regarded as introducing subject-matter which extends beyond the content of the application as filed if the overall change in the content of the application results in the skilled person being presented with information which differs from that previously presented in the specification". This necessarily means that it depends upon the view of the skilled person whether or not it would be permissible to combine the disclosure of two separate parts of the specification. An absolute prohibition of such a combination therefore cannot be seen as a consequence of the aforementioned statement.

4. The characterising part of the pending claim 1 is that a C18-24 alkenylsuccinic mono-oxazoline or a C18-24 alkenylsuccinic bis-oxazoline is present in a lubricant composition. The argument is about the C18-24 alkenylsuccinic bis-oxazoline. In the original specification alkenylsuccinic mono- oxazolines as well as alkenylsuccinic bis-oxazolines are disclosed in general. According to page 1, lines 13-16, they are prepared by reacting one mole of a ClO-50 alkenylsuccinic acid with one mole (which gives rise to a mono-oxazoline) or two moles (which gives rise to a bis-oxazoline) of tris(hydroxymethyl)aminomethane (or THAM). There is a specific disclosure of isooctadecenyl suc- succinic bis-oxazoline, a C18 alkenylsuccinic bis- oxazoline, in the original example 2 (now example 1) and the original claim 3 (now claim 2). In example 3 (now example 2) the reaction 1 mole C18-24 dimer alkenylsuccinic anhydride with 1 mole THAM is disclosed, which leads to a C18-24 dimer alkenylsuccinic monooxazoline. According to page 1, lines 13-16 of appellant's letter of 17 November 1982, this product is a mixture of individual C18-24 compounds, the C18-24 moiety originating from a commercially available mixture and the term "dimer" denoting the source thereof. In claim 1 a C18-24 alkenylsuccinic mono-oxazoline is claimed, which includes all individual C18-24 members involved as well as mixtures thereof. Example 3 (now example 2) is considered to be a sound basis for this part of the claim. The question whether or not the disclosure of a C18-24 alkenylsuccinic mono-oxazoline implicitly discloses a C18-24 alkenylsuccinic bis-oxazoline, in this case should be answered taking into account whether or not a distinction was made between the mono- and bis-oxazolines. On the basis of the original specification, such a distinction cannot be said to exist.

5. In his Statement of Grounds, the appellant, rightly in the view of the Board, states that in answering the aforementioned question, the state of the art may be taken into account, too. From this state of the art, the only conclusion that can be drawn is that alkenylsuccinic mono- and bis-oxazolines go hand in hand. French patent specification No. 2 281 423 discloses the reaction of one mole of an alkenylsuccinic anhydride and one mole of THAM to provide a mono-oxazoline in example 2, and with two moles of THAM to provide a bis-oxazoline in example 3. According to page 2 lines 27-28, the quantity of THAM can even vary from 0.05 to 5 moles. US patent specification No. 4 035 309 discloses the preparation of a mono- and bis-oxazoline (claim 1, column 3, lines 55-59). A mono-oxazoline derived from THAM (column 3, lines 49-50) is disclosed in claim 8 (see also column 5, lines 16-20), and an equivalent bis-oxazoline in claims 2, 6 and 10.

6. Only the appellant's argument that disclosure of ClO-50 implicitly discloses C18-24 fails. Disclosure of ClO-50 discloses a summation of all individual members ClO...Cll...... C50 indeed. However, the difference is that C18-24 discloses a summation of the members C18...C19 .....C24 disregarding all members outside this area whereas ClO-50 discloses a summation of all individual members comprised without disregarding any of them.

7. As a matter of fact claim 1 is broader than the claim 1 effective at the date of lodging of the appeal since the term "dimer" in "a C18-24 dimer alkenylsuccinic mono-oxazoline" is deleted. This is accepted by the Board as an admissible correction of an obvious error. As stated in the appellant's letter of 27 November 1982, page 1, lines 13-16, the term "dimer" denotes the composition's derivation rather than its final structure. Since the mono- and bis-oxazolines go hand in hand, a distinction of this kind between them is not logical.

8. Reimbursement of appeal fees may be ordered where a Board of Appeal deems an appeal to be allowable, if such reimbursement is equitable by reason of a substantial procedural violation: Rule 67 EPC. Since the decision of the Examining Division is based only upon an incorrect consideration such a violation cannot be said to exist. It follows that the request for reimbursement of the appeal fee made in the statement of grounds of 10 February 1982 must be rejected. The Board rules that the amendment in claim 1 does not violate Article 123(2) EPC and considers the appeal allowable.